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ABSTRACT 
 
The use of lipids in drug delivery is not a new trend, some of the lipid dosage forms have been in use for a 
long time such as suppositories, creams, and emulsions. However, there has been much advancement in the 
designs of lipid carriers over the past decade. In the same way from the past two decades, new approaches 
in biodegradable and bio-reducible polymers have paved a way for many recent drug delivery systems. 
Applications of these novel drug delivery formulations have been promising clinically. However, each 
system has its pros and cons in various factors depending upon their use and intended route of 
administration. This review focuses on upbringing the challenges in the use of novel lipid and polymer drug 
delivery systems in clinical settings and few insights on how to overcome them. 
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INTRODUCTION 
In pharmaceutical technology, lipids and polymers 
have always been the vital components of drug 
delivery and dosage forms [1]. They can be used in 
many ways such as stabilizers, solubilizers, 
permeation enhancers, release rate modifiers, and 
also targeted systems. In the early day's lipids and 
polymers were derived from various natural sources 
but with advancements and development in 
chemistry, the drug formulators now use a variety of 
natural, semi-synthetic, and also completely man-
made lipids and polymers manufactured in various 
types for use in different routes such as oral, topical, 
etc. Lipids and polymers have similar roles despite 
their structural differences and quality by design 
approach is followed to ensure safety of product [2]. 
New applications of lipids in fields such as gene 
therapy and new methods of improving circulation in 
the body blood flow by stabilization are also being 
proven efficient [3]. 
Novel lipid-based nanoformulations such as 
nanostructured lipid carriers and solid lipid 
nanoparticles have been proven to be a recent 
breakthrough in many aspects. Nanofibres that are 
manufactured through electrospining are also 
proving to be efficient in cancer diagnosis, tissue 
engineering etc [4,5,6]. However, when it comes to 
usage of these drug delivery systems through various 
routes in real-time clinical settings and hospitals, few 
challenges need to be addressed [7]. Certain side 
effects and adverse outcomes are being reported by 
the usage of these novel drug delivery systems in 
clinical settings. Although many of these drug 
delivery systems reach the clinical trials phase, some 
of them don’t show expected and desirable results 
and can’t succeed the phase 4 of clinical trials. Certain 
steps are followed by manufacturers to ensure the 
safety of using these drug delivery systems. High-
performance liquid chromatography (HPLC) is used 
for the analysis [8,9,10]. 
Novel lipid based drug delivery systems 
The main objective of using lipid-based drug delivery 
systems is to improve the bioavailability and to 
promote better solubility as well as the distribution 
of poor water-soluble drugs [11]. Lipid-based 
formulations can be efficiently designed to meet 
many requirements such as solubility, cost-efficacy, 
bioavailability, route of administration, and toxicity. 
Lipid-based drug delivery system can be used for 
routes including oral, topical, vaginal, parental, 
ocular, and also intranasal. For example proliposomal 
gel is used for rheumatoid arthritis for sustained 
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release of drug. [12,13] However the most preferred 
route is oral. A recent novel approach for the oral 
lipid drug delivery system is lipid nanocarriers. The 
recent developments are in motion in solid lipid 
nanoparticles (SLN’s), Nanostructured lipid carriers 
(NLC’s), Lipid drug conjugate (LDC’s), Self nano 
emulsifying drug delivery system (SNEDDS) [14,15,16]. 
These nanoparticles have opened up a way for the 
treatment of cancer through options such as gene 
therapy through siRNA. High Profile Liquid 
Chromatography is used for quantitative and 
qualitative isolation of lipids. The main exponents for 
lipid-based formulations are: 1) Solubility, 2) 
Dispersion, 3) Digestion, 4) Absorption. [1718] 
Trends in novel lipid based drug delivery systems 
Recent technological advancements in medicine and 
discoveries in pharmacology have made possible 
many new lipid-based drug delivery systems and 
paved a way for efficient treatment methods for can-
cers too [19]. Lipid-based drug delivery systems are 
nowhere to be considered as new because they have 
been in use for a very long time. But recent and main 
advancements have occurred over the past decade 
with breakthrough discoveries. [20] 
Recent trends in the lipid-based drug delivery 
systems are nano particles with limelight focused 
upon solid lipid nanoparticles and nanostructured 
lipid carriers [21,22]. These two along with hybrid 
nanoparticles have gained much interest as drug 
delivery systems because of their capacity to hold and 
release drugs of Class 2 (High Permeability and Low 
Solubility)[23] and Class 4(Low Permeability and Low 
Solubility)[24] from the Biopharmaceutical 
Classification System (BCS). Many novel liposomal 
drug formulations are already in late-stage clinical 
trials for cancer treatment as they have been proven 
effective in improvising the efficacy and safety of 
chemotherapeutic agents for cancer treatment. [25] 
Specific targeted drug delivery is the main goal for 
any discovery and that is made possible by 
temperature-sensitive liposomes (TSL’s) that helps 
in minimizing the clearance and non-specific uptake. 
ThermoDox (Celsion) is showing promising results in 
drug uptake and release rate in heated tumors. 
Magnetic resonance-guided focused ultrasound is 
being combined with TSL to promote better efficacy 
of localized chemotherapy. Prolopisomes, defined as 
free flowing particles in a dispersed system can 
immediately convert into liposomal suspension as 
soon as it comes in contact with water. [26,27,28] 
Nanocarrier based delivery of platinum compounds 
for cancer treatment in the field with most extensive 
research and clinical trials under progress which 
would revolutionize the platinum chemotherapy. 
Some other innovations of lipids are, nanofibres 
which bought a revolution in tissue engineering. Also 
nano ethosomes which carry bioactive agents and 
help penetrate them deep into the layers of skin. [29] 
Novel polymer based drug delivery systems 
Polymer-based drug delivery systems have gained 
major advancements in the past two decades. It can 
be defined as a formulation used to introduce a drug 
into the body. Biodegradable and bio reducible 
polymers have made possible a choice for many new 
drug delivery systems. [30] For polymer-based drug 
delivery systems natural polymers such as 
polysaccharides, dextrin, chitosan (obtained from 
shellfish) [31], arginine, alginate (derived from brown 
seaweed known as Phaeophyceae), Zein (found in 
corn) and hyaluronic acid are used. Synthetic 
polymers such as dendrite polymers, 2-hydroxyethyl 
methacrylate, PLGA (elastomeric copolymer) and N-
isopropyl acrylamide are used. Targeting polymeric 
drug delivery and biomimetic and bio-related 
polymeric systems are also used in polymeric based 
drug delivery.[32,33,34] The polyethyleneimine 
derivatives are used as a system for non-viral vectors 
for gene delivery also polyethyleneimine copolymer. 
Polyvinylpyrrolidone (PVP) is also being studied as 
excipient from conventional to controlled delivery 
systems for COVID-19 inhibition.[35] Systems for viral 
vectors are DNA conjugates and RNA conjugates for 
gene delivery. In situ gel is an effective polymer based 
drug delivery system for ophthalmic purposes.[36] 
Trends in novel polymer based drug delivery sys-
tems 
Smart polymers can be said as the current 
breakthrough in the drug delivery system from the 
past decade. The ultimate aim for a manufacturer of 
any drug or any invention of formulation and drug 
delivery system is to provide a site-specific or 
targeted drug for anything, recent advancements in 
the polymeric drug delivery system have made this 
possible. For example Alginate is multifunctional 
with its uses ranging from impression making in 
dentistry and also in preparation of reflux inhibiting 
medications.[37,38] Zein another natural polymer is 
used for targeted drug delivery, gene delivery and 
also vaccinations. Smart polymers are gaining 
momentum, and researchers are interested as the 
discoveries in the chemistry by scientists are paving 
a way for innovation of controlled release drug 
systems and drugs that sense environmental and 
biological changes. [39,40] The smart polymers such as 
pH-sensitive polymers, temperature-sensitive 
polymers, polymers with dual stimuli 
responsiveness, phase-sensitive polymers, and light-
sensitive smart polymers are the major discoveries in 
the past 10 years that made possible a ton of new 
efficient ways for treatment. Biomimetic and 
bioinspired systems are used to improve the 
biocompatibility during drug delivery. [41] 
Dendrimers, these polymers with well defined 
molecular weight and multi-branching are showing 
promising results for further aspects of polymeric 
drug delivery systems. The viral and non-viral 
vectors for polymeric gene delivery are promising for 
cancer treatment and have the potential to be an 
important tool for human gene therapy too. Okra 
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thioglycolic acid is used as a mucoadhesive polymer 
and is multifunctional.[42] Chitosan a naturally 
obtained polymer is also proven to be effective in 
weight loss. [43] 
Clinical implications by using lipid/ polymer drug 
delivery systems 
Although Lipid and Polymeric drug delivery systems 
are considered as one of the greatest advancements 
in the past decade there are many challenges when it 
comes to real-time clinical setting. Many of these new 
delivery systems are not being successful in phase 
4clinical trials. [44,45] 
Disadvantages and limitations of lipid based drug 
delivery systems 
Every system has pros and cons to go with. There are 
certain disadvantages for lipid-based drug delivery 
systems, some of them are: 
1. API Instability: API Instability is seen in certain 
formulations; research is still ongoing to consider 
the factors that promote API stability. [46] 
2. Excipient shell compatibility issues: This 
compatibility issues and interactions may have 
effects on bioavailability, stability, and chemical 
also physical factors of the drug or dosage. [47,48] 
3. Uncontrolled drug precipitation post-dosing: 
This may have normal therapeutic failure or 
serious effects on the patients by either 
embolization ranging from thrombophlebitis or 
multiple organ failure and even death. [49] 
4. Inadequate drug loading in the lipid drug 
delivery system: This is also a major setback in 
the formulation of the lipid-based drug delivery 
system which may lead to inefficient therapeutic 
effects. [50, 51] 
5. Drug burst release by erosion mechanism. [52] 
6. Drug expulsion. [45] 
7. Accumulation of lipids in the liver and spleen may 
cause pathological alteration with certain lipid 
nanoparticles. [53] 
8. Enhanced permeability and retention effect (EPR) 
may vary significantly from one human patient to 
another. [4] 
Disadvantages and limitations of polymeric 
based drug delivery systems 
1. Insufficient literature of toxicological assess-
ment[54] 
2. Can be only used for lipophilic drugs [55] 
3. Low drug loading capacity [56] 
4. Elimination and mechanism depending upon the 
materials and generation [57,58]  
5. High cost for their synthesis [52] 
6. Chances of cellular toxicity [36] 
7. Difficult to maintain the integrity of synthetic 
and natural polymers in the body in genetic en-
gineering or in vivo treatments [53] 
8. Complex and multistep process [38, 52] 
Safety, efficacy, and success rate of lipid and poly-
mer based drug delivery system 
The new approaches to drug delivery system in terms 
of polymer and lipid-based are successful in the 
clinical trials phase with in vivo and genetic 
engineering advancements. [56] Post-marketing 
surveillance report, however, vary in some of these 
drug delivery systems as the EPR and other factors 
vary from human to human and also a lot of other 
factors needs to be characterized to formulate a 
successful system that works for all the humans 
similarly. [59] To ensure the safety of these drug 
delivery systems the formulators and manufacturers 
make sure to strike off the factors that may arise any 
further complications. [60] However more literature 
and more trials need to be done to determine the 
factors that may promote or demote the efficacy of 
the drug in the patients and prevent any unwanted 
adverse effects. 
CONCLUSION 
Since their discovery lipids and polymers have ad-
vanced rapidly technologically from being used as an 
apparatus for cell membranes to versatile drug carri-
ers. These drug delivery systems have emerged as a 
promising strategy for new-age drug delivery sys-
tems including potential cancer treatment. Many for-
mulations are being investigated in different phases 
of clinical trials and awaiting approval while many 
others are already been approved and commercially 
available. However, the post surveillance reports 
show certain setbacks. Further studies and clinical 
trials are warranted to completely optimize their po-
tential as drug delivery systems and to overcome the 
setbacks and challenges these two drug delivery sys-
tems are facing in the real-time clinical settings. 
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